International Medical Research Frontier

Objective To investigate the effect of low molecular weight heparin anticoagulation in ICU sepsis. Methods Fifty patients with ICU sepsis treated in our hospital from January 2018 to June 2021 were randomly divided into two groups, with 25 patients in each group. The reference group was treated with conventional drugs, and the study group used low molecular weight heparin anticoagulation. Comparative analysis of the treatment response rate and the incidence of adverse reactions in the two groups. Results The treatment effect of the patients in the study group was better than that of the patients in the reference group, and the difference was statistically significant (P<0.05). The incidence of adverse reactions in the study group after treatment was lower than that in the reference group, and the difference was statistically significant (P<0.05). The coagulation function indexes (PT, APTT, FIB) of the two groups of patients after treatment were better than those before treatment, and the coagulation function indexes (PT, APTT, FIB) of the study group after treatment were better than those of the reference group, and the difference was statistically significant (P<0.05). Conclusion The use of low molecular weight heparin anticoagulation in the treatment of ICU sepsis patients has a significant clinical effect, which is better than conventional drug treatment, and is worthy of further clinical promotion.

Low molecular heparin anticoagulation; ICU sepsis